Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Yahoo Finance ·

Pfizer ( PFE +2.58% ) is offering dividend investors a huge 6.9% yield. To put that into perspective, the S&P 500 index ( ^GSPC 0.05% ) has a tiny 1% yield right now, and the average pharmaceutical stock's yield is 1.6%. Dividend lovers will clearly find Pfizer's yield attractive. However, that lofty yield is also a sign that this pharmaceutical company is deeply out of favor on Wall Street. If you have a long-term investment approach that allows you to practice what I call time arbitrage, you may want to consider buying this high-yield drugmaker. Pfizer's stock price is rough 60% below its late 2021 high. In fact, the share price is lower today than it was prior to the coronavirus pandemic. That's actually quite important, because Pfizer was one of the companies to develop a COVID vaccine. In typical Wall Street fashion, investors bid up the price, thinking that COVID would forever be a health scourge. Only the world learned to live with the illness, and vaccine sales didn't live up to lofty investor expectations. The stock dropped, as you would expect. However, at the same time, Pfizer has also been struggling to develop new drugs to replace blockbusters that are set to lose patent protection in the next couple of years. Its biggest miss came in 2025, when it had to abandon a GLP-1 weight-loss drug it was working on. That wasn't a good look and leaves the company far behind its industry peers, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), in this emerging new drug category.

DYAX Investor Sentiment

Bullish (Long) 43% · Bearish (Short) 57%

323 participants

Related News

원문 보기 — Yahoo Finance